

DAFTAR PUSTAKA

- Alomar, M.J., 2014. Factors Affecting the Development of Adverse Drug Reactions. *Saudi Pharmaceutical Journal*, **22**: 83–94.
- American Cancer Society, 2022. About Lung Cancer. *American Cancer Society*, .
- Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., dkk., 2012. Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. *Clinical Medicine Insights: Oncology*, **6**: CMO.S7340.
- Araya, T., Kasahara, K., Demura, Y., Matsuoka, H., Nishitsuji, M., dan Nishi, K., 2013. Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer. *Lung Cancer*, **80**: 344–346.
- Armour, A.A. dan Watkins, C.L., 2010. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. *European Respiratory Review*, **19**: 186–196.
- Arora, A.K., 2011. Erlotinib-induced Hepatotoxicity—Clinical Presentation and Successful Management: A Case Report. *Journal of Clinical and Experimental Hepatology*, **1**: 38–40.
- ASCO, 2021. ASCO Answer: Non-Small Cell Lung Cancer. *American Society of Clinical Oncology*, 44.
- Aw, D.C.-W., Tan, E.H., Chin, T.M., Lim, H.L., Lee, H.Y., dan Soo, R.A., 2018. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. *Asia-Pacific Journal of Clinical Oncology*, **14**: 23–31.
- Barni, S., Cabiddu, M., Guarneri, P., Lonati, V., dan Petrelli, F., 2012. The Risk for Anemia with Targeted Therapies for Solid Tumors. *The Oncologist*, **17**: 715–724.
- Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D.G., dkk., 2002. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types. *Journal of Clinical Oncology*, **20**: 4292–4302.
- Beniwal, R., Gupta, L., Khare, A., Mittal, A., Mehta, S., dan Balai, M., 2019. Clinical profile and comparison of causality assessment tools in cutaneous adverse drug reactions. *Indian Dermatology Online Journal*, **10**: 27.
- Beom, S.-H., Kim, D.-W., Sim, S.H., Keam, B., Park, J.H., Lee, J.-O., dkk., 2016. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. *Cancer Research and Treatment*, **48**: 88–97.
- Bereda, G., 2021. Classifying Causality of an Adverse Drug Reaction: Naranjo Algorithm. *International Journal of Pharmacy and Chemistry*, **7**: 125.
- Bethesda, 2018. Gefitinib. *National Institute of Diabetes and Digestive and Kidney Disease*, .
- BPOM, 2020. Modul Farmakovigilans Bagi Tenaga Profesional Kesehatan. *Badan Pengawas Obat dan Makanan*, .
- Buana, I. dan Harahap, D.A., 2022. Asbestos, Radon dan Polusi Udara sebagai Faktor Resiko Kanker Paru pada Perempuan Bukan Perokok. *AVERROUS: Jurnal Kedokteran dan Kesehatan Malikussaleh*, **8**: 1.

- Cancer Council Australia, 2020. Understanding Lung Cancer: A Guide for People with Cancer, Their Families and Friends. *Cancer Council*, .
- Cersosimo, R.J., 2006. Gefitinib: an adverse effects profile. *Expert Opinion on Drug Safety*, **5**: 469–479.
- CTCAE, 2017. Common Terminology Criteria for Adverse Events (CTCAE) 155.
- Detterbeck, F.C., 2018. The eighth edition TNM stage classification for lung cancer: What does it mean on main street? *The Journal of Thoracic and Cardiovascular Surgery*, **155**: 356–359.
- Dewi, A., Thabrany, H., Satrya, A., Puteri, G.C., Fattah, R.A., dan Novitasari, D., 2021. Kanker Paru, Kanker Paling Mematikan di Indonesia: Apa Saja yang Telah Kita Atasi dan Apa yang Kita Bisa Lakukan 29.
- Ding, P.N., Lord, S.J., GebSKI, V., Links, M., Bray, V., Gralla, R.J., dkk., 2017. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **12**: 633–643.
- DiPiro, J.T. (Editor), 2020. *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh edition. ed. McGraw Hill Medical, New York.
- Du, Y., Cui, X., Sidorenkov, G., Groen, H.J.M., Vliegenthart, R., Heuvelmans, M.A., dkk., 2020. Lung cancer occurrence attributable to passive smoking among never smokers in China: a systematic review and meta-analysis. *Translational Lung Cancer Research*, **9**: 204–217.
- Groot, P.M., Wu, C.C., Carter, B.W., dan Munden, R.F., 2018. The epidemiology of lung cancer. *Translational Lung Cancer Research*, **7**: 220–233.
- He, Y., Zhao, C., Li, X., Ren, S., Jiang, T., Zhang, J., dkk., 2017. P1.03-052 Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism. *Journal of Thoracic Oncology*, **12**: S1971.
- Hidalgo, M., Siu, L.L., Nemunaitis, J., Rizzo, J., Hammond, L.A., Takimoto, C., dkk., 2001. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies. *Journal of Clinical Oncology*, **19**: 3267–3279.
- Hirsch, F.R., Sequist, L.V., Gore, I., Mooradian, M., Simon, G., Croft, E.F., dkk., 2018. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP): Long-Term NSCLC Survival With Gefitinib. *Cancer*, **124**: 2407–2414.
- Hirsh, V., Blais, N., Burkes, R., Verma, S., dan Croitoru, K., 2014. Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *Current Oncology*, **21**: 329–336.
- Holcman, M. dan Sibilia, M., 2015. Mechanisms underlying skin disorders induced by EGFR inhibitors. *Molecular & Cellular Oncology*, **2**: e1004969.

- Jamaluddin, M. 2015. Efikasi dan Toksisiti Erlotinib/Gefitinib sebagai Terapi Lini Kedua pada Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil. Jakarta: Fakultas Kedokteran Universitas Indonesia Program Studi Pulmonologi dan Ilmu Kedokteran Respirasi.
- Kainis, I., Syrigos, N., Kopitopoulou, A., Gkiozos, I., Filiou, E., Nikolaou, V., dkk., 2018. Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival. *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, **26**: 59–69.
- Kemenkes RI, 2018. Pedoman Pengendalian Faktor Risiko Kanker Paru. *Direktorat Pencegahan dan Pengendalian Penyakit Tidak Menular Kementerian Kesehatan Republik Indonesia*, .
- Kim, M.K., Yee, J., Cho, Y.S., Jang, H.W., Han, J.M., dan Gwak, H.S., 2018. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. *BMC Cancer*, **18**: 988.
- Köhler, J. dan Schuler, M., 2013. Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review. *Oncology Research and Treatment*, **36**: 510–518.
- Kozuki, T., 2016. Skin problems and EGFR-tyrosine kinase inhibitor. *Japanese Journal of Clinical Oncology*, **46**: 291–298.
- Krampera, M., Pasini, A., Rigo, A., Scupoli, M.T., Tecchio, C., Malpeli, G., dkk., 2005. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. *Blood*, **106**: 59–66.
- Lewkowicz, P., Tchórzewski, H., Dytnerka, K., Banasik, M., dan Lewkowicz, N., 2005. Epidermal growth factor enhances TNF- α -induced priming of human neutrophils. *Immunology Letters*, **96**: 203–210.
- Li, J., Zhao, M., He, P., Hidalgo, M., dan Baker, S.D., 2007. Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. *Clinical Cancer Research*, **13**: 3731–3737.
- Li, M., Zhang, Q., Liu, L., Liu, Z., Zhou, Z., Wang, Z., dkk., 2011. The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. *Neoplasma*, **58**: 74–81.
- Liang, Y.-C., Wu, G., Cheng, J., Yu, D.-D., dan Wu, H.-G., 2015. Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report. *Oncology Letters*, **10**: 1277–1280.
- Liu, H., Wu, Y., Lv, T., Yao, Y., Xiao, Y., Yuan, D., dkk., 2013. Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. *PLoS ONE*, **8**: e55128.
- Liu, Y., Zhang, Y., Feng, G., Niu, Q., Xu, S., Yan, Y., dkk., 2017. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis. *Experimental and Therapeutic Medicine*, .

- Ma, Y., Huang, Y., Zhao, H., Liu, J., Chen, L., Wu, H., dkk., 2013. The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Patients.
- Mastroianni, P. dan Varallo, F., 2015. Risk factors to early predict adverse drug events related to hospitalizations. *Revista Vitae*, **22**: .
- Menkes RI, 2017. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. *Kementerian Kesehatan Republik Indonesia*, .
- Menkes RI, 2022. Pedoman Nasional Pelayanan Kedokteran Tatalaksana Karsinoma Sel Hati.
- Mudigubba, M.K., Rajashekarachari, Y., dan Dahiya, S., 2017. Risk Factors Associated with Adverse Drug Reactions in Hospitalized Patients. *International Journal of Pharmaceutical Sciences and Research*, **8**: 8.
- Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., dkk., 1981. A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology and Therapeutics*, **30**: 239–245.
- Olayan, A., Al Hussaini, H., dan Rahman Jazieh, A., 2012. The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. *Journal of Infection and Public Health*, **5**: S50–S60.
- PDPI, 2003. Kanker Paru: Pedoman Diagnosis dan Tata Laksana di Indonesia. *Perhimpunan Dokter Paru Indonesia*, .
- Peters, S., Zimmermann, S., dan Adjei, A.A., 2014. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions. *Cancer Treatment Reviews*, **40**: 917–926.
- Petrelli, F., Borgonovo, K., Cabiddu, M., Lonati, V., dan Barni, S., 2012. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. *Lung Cancer*, **78**: 8–15.
- Pont, L., Alhawassi, T., Bajorek, B., dan Krass, I., 2014. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. *Clinical Interventions in Aging*, 2079.
- Recuero, J.K., Fitz, J.R., Pereira, A.A., dan Bonamigo, R.R., 2023. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects. *Anais Brasileiros de Dermatologia*, S036505962300051X.
- Rezende de Menezes, R., Graciano Silva, M. das D., Pinho Ribeiro, A.L., Martins Pinto Filho, M., Martinho, G.H., Carvalho Ferreira, L.E., dkk., 2021. Causality assessment of adverse drug reactions by applying a global introspection method in a high complexity hospital. *Exploratory Research in Clinical and Social Pharmacy*, **3**: 100064.
- Ricciardi, S., 2010. Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. *Lung Cancer: Targets and Therapy*, 1.
- Rukzenkov, Y., Speake, G., Marshall, G., Anderton, J., Davies, B.R., Wilkinson, R.W., dkk., 2009. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? *Anti-Cancer Drugs*, **20**: 856–866.

- Salopek, T., Morris, D., Easaw, J., dan Surgeoner, B., 2020. Prevention and Treatment of Acneiform Rash in Patients Treated with EGFR Inhibitor Therapies.
- Scheffler, M., Gion, P.D., dan Doroshenko, O., 2011. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. *Clin Pharmacokinet*, .
- Secombe, K.R., Van Seville, Y.Z.A., Mayo, B.J., Collier, J.K., Gibson, R.J., dan Bowen, J.M., 2020. Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. *Integrative Cancer Therapies*, **19**: 153473542092849.
- Shah, N.T., Kris, M.G., Pao, W., Tyson, L.B., Pizzo, B.M., Heinemann, M.-H., dkk., 2005. Practical Management of Patients With Non-Small-Cell Lung Cancer Treated With Gefitinib. *Journal of Clinical Oncology*, **23**: 165–174.
- Shepherd, F.A., Hirsh, V., Smylie, M., Findlay, B., dan Santabárbara, P., 2005. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. *The New England Journal of Medicine*, 10.
- Shin, H.-J., Kim, T.-O., Kang, H.-W., Chi, S.-Y., Ban, H.-J., Kim, S.-O., dkk., 2011. Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer. *Tuberculosis and Respiratory Diseases*, **71**: 15.
- Siddiqui, I.A., Sanna, V., Ahmad, N., Sechi, M., dan Mukhtar, H., 2015. Resveratrol nanoformulation for cancer prevention and therapy: Resveratrol nanoformulations for cancer. *Annals of the New York Academy of Sciences*, **1348**: 20–31.
- Stathopoulos, G.P., Trafalis, D., Athanasiou, A., Bardi, G., dan Chandrinou, H., 2010. Serious Hematologic Complications Following Erlotinib Treatment. *Anticancer Research*, 4.
- Stegmaier, K., Corsello, S.M., Ross, K.N., Wong, J.S., DeAngelo, D.J., dan Golub, T.R., 2005. Gefitinib induces myeloid differentiation of acute myeloid leukemia. *Blood*, **106**: 2841–2848.
- Sun, Y.Q., Chen, Y., Langhammer, A., Skorpen, F., Wu, C., dan Mai, X.M., 2017. Passive smoking in relation to lung cancer incidence and histologic types in Norwegian adults: The HUNT study. *European Respiratory Journal*, **50**: 7–10.
- Thomas, P., Vincent, B., George, C., Joshua, J., Pavithran, K., dan Vijayan, M., 2019. A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients. *Indian Journal of Medical Research*, **150**: 67.
- Umara, A.F., Wulandari, I.S., Supriadi, E., Rukmi, D.K., dan Silalahi, L.E., 2021. *Keperawatan Medikal Bedah Sistem Respirasi*. Yayasan Kita Menulis.
- Veeragoni, S. dan Mathur, A., 2016. Grading Lab Toxicities using NCI- Common Terminology Criteria for Adverse Events (CTCAE) 10.
- WHO, 2020. International Agency for Research on Cancer: Indonesia. *World Health Organization*, .
- Wu, S.-G. dan Shih, J.-Y., 2018. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. *Molecular Cancer*, **17**: 38.

- Wulandari, F., Utami, W., Rohana, E., dan Prabhata, W.R., 2021. Efikasi Terapi Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKIs) pada Kanker Paru. *Generics: Journal of Research in Pharmacy*, **1**: .
- Wulandari, L., Febriani, A., Fatmawati, F., dan Soegiarto, G., 2018. Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor. *Asian Journal of Oncology*, **04**: 048–053.
- Yang, J.C.-H., Reguart, N., Barinoff, J., Köhler, J., Uttenreuther-Fischer, M., Stammberger, U., dkk., 2013. Diarrhea associated with afatinib: an oral ErbB family blocker. *Expert Review of Anticancer Therapy*, **13**: 729–736.
- Yano, Y., Namba, Y., Mori, M., Nakazawa, Y., Nashi, A., Kagami, S., dkk., 2012. Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. *Lung Cancer International*, **2012**: 1–6.
- Yoon, H.-Y., Ryu, J.-S., Sim, Y.S., Kim, D., Lee, S.Y., Choi, J., dkk., 2020. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. *PLOS ONE*, **15**: e0228925.
- Yoshida, T., Yamada, K., Azuma, K., Kawahara, A., Abe, H., Hattori, S., dkk., 2013. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. *Medical Oncology*, **30**: 349.
- Zazzara, M.B., Palmer, K., Vetrano, D.L., Carfi, A., dan Onder, G., 2021. Adverse drug reactions in older adults: a narrative review of the literature. *European Geriatric Medicine*, **12**: 463–473.
- Zhang, S., Liang, F., dan Tannock, I., 2016. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. *BMC Cancer*, **16**: 392.
- Zhang, W., Wei, Y., Yu, D., Xu, J., dan Peng, J., 2018. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis. *BMC Cancer*, **18**: 780.
- Zhou, J.-G., Tian, X., Cheng, L., Zhou, Q., Liu, Y., Zhang, Y., dkk., 2015. The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis. *Medicine*, **94**: e1719.
- Zhong, S. 2020. Get to the Bottom of Lab Toxicity Grading: Challenges and Implementation of CTCAE Version 5. The Clinical Data Science Conference.